Previous 10 | Next 10 |
home / stock / mdnaf / mdnaf news
Medicenna Therapeutics Corp. [TSX:MDNA] ( OTCQB:MDNAF ) is a Toronto based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines. Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing protei...
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study Canada NewsWire TORONTO and HOUSTON, March 25, 2020 Conference call and webcast today at 10:00AM EST to discuss MDNA19 results with pre-clinical experts showing robust im...
Medicenna Announces Closing of Public Offering of $35 Million Canada NewsWire TORONTO and HOUSTON, March 17, 2020 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , March 17, 2020 /CNW/ - Medicenna T...
Medicenna Announces Intention to File Final Short Form Prospectus Canada NewsWire TORONTO and HOUSTON, March 12, 2020 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , March 12, 2020 /CNW/ - Medice...
Medicenna Therapeutics Corp. [TSX:MDNA] (MDNAF) is a Toronto based clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™. Superkines can be engineered as short or long-acting therapeutics or fused with cell killing protei...
Medicenna Reports Third Quarter Fiscal 2020 Financial Results Canada NewsWire TORONTO and HOUSTON, Feb. 13, 2020 TORONTO and HOUSTON , Feb. 13, 2020 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or the " Company ") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immun...
Phoenix, Arizona--(Newsfile Corp. - January 21, 2020) - The Stock Day Podcast welcomed Medicenna Therapeutics Corp. (TSX: MDNA) (OTCQB: MDNAF) ("the Company"), a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versio...
Survival improvement of over 150% seen in MDNA55 subjects compared to a Synthetic Control Arm TORONTO and HOUSTON , Jan 13, 2020 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, to...
Medicenna Receives $1.3 Million Through Early Warrant Exercises Canada NewsWire TORONTO and HOUSTON, Jan. 8, 2020 TORONTO and HOUSTON , Jan. 8, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immu...
- MDNA55 achieves up to 5 fold increase in 12 month survival rate in aggressive, chemotherapy resistant glioblastoma when compared to approved therapies TORONTO and HOUSTON , Dec. 12, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX...
News, Short Squeeze, Breakout and More Instantly...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL...